Acquired erythropoietic uroporphyria secondary to myelodysplastic syndrome with chromosome 3 alterations: a case report

Br J Dermatol. 2018 Aug;179(2):486-490. doi: 10.1111/bjd.15927. Epub 2018 Mar 2.

Abstract

Congenital erythropoietic porphyria is a rare autosomal recessive disease caused by a deficiency of uroporphyrinogen III synthase, owing to mutations in UROS in chromosome 10. Occasionally, patients show a mild, late-onset disease, without germline UROS mutations, associated with haematological malignancies. We report a 65-year-old patient with photosensitivity, overexcretion of porphyrins and thrombocytopenia. Bone marrow analysis gave a diagnosis of myelodysplastic syndrome (MDS) with the presence of a derivative chromosome 3, possibly due to an inversion including 3q21 and 3q26 break points. After allogeneic stem-cell transplantation, complete remission of MDS and uroporphyria was achieved. To our knowledge, this is the first reported case of acquired erythropoietic uroporphyria associated with MDS, with chromosome 3 alterations.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antimetabolites, Antineoplastic / therapeutic use
  • Azacitidine / therapeutic use
  • Blood Transfusion
  • Bone Marrow / pathology
  • Bone Marrow Transplantation
  • Chromosome Inversion
  • Chromosomes, Human, Pair 3 / genetics*
  • Humans
  • Late Onset Disorders / diagnosis*
  • Late Onset Disorders / etiology
  • Late Onset Disorders / pathology
  • Late Onset Disorders / therapy
  • Male
  • Myelodysplastic Syndromes / complications
  • Myelodysplastic Syndromes / diagnosis*
  • Myelodysplastic Syndromes / genetics
  • Myelodysplastic Syndromes / therapy
  • Porphyria, Erythropoietic / diagnosis*
  • Porphyria, Erythropoietic / etiology
  • Porphyria, Erythropoietic / pathology
  • Porphyria, Erythropoietic / therapy
  • Porphyrins / blood
  • Porphyrins / urine
  • Skin / pathology
  • Treatment Outcome

Substances

  • Antimetabolites, Antineoplastic
  • Porphyrins
  • Azacitidine